Strategic alliance Leverage Akashi Therapeutics' history of partnerships (Grünenthal collaboration and Processa licensing) to position co-development or licensing opportunities for HT-100 and DT-200 with pharma partners seeking fibrosis, inflammation, and muscle regeneration programs.

Rare disease focus Target discussions with specialty biotech and patient-centric organizations focusing on Duchenne muscular dystrophy and other rare pediatric diseases, highlighting opportunities for HT-100 aimed at fibrosis reduction and muscle regeneration, and DT-200 as a muscle-building SARM.

Clinical stage leverage Position Akashi as a potential partner for late-stage or milestone-driven collaborations, offering access to an early-stage portfolio with clear translational potential in anti-fibrotic and anti-inflammatory therapies, suitable for co-development or out-licensing deals.

Funding and risk Note limited current funding and lean team size, presenting a financial rationale for strategic partnerships, non-dilutive funding avenues, and collaboration structures that minimize upfront costs while advancing HT-100 and DT-200 development.

Market readiness Explore opportunities with CROs, contract manufacturers, and translational research partners to scale preclinical and early clinical activities, given the small but experienced leadership team and the need to accelerate clinical milestones for fibrosis and muscle disease programs.